SCHEMBL3503452

SCHEMBL3503452

COC(=O)C(N)(C(=O)OC(C)(C)C)c1ccc(C(=O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 2/20 0.44
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 1/20 0.43
NR1H4 Q96RI1 3/20 0.42
EPHX2 P34913 2/20 0.42
DGAT1 O75907 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
RXRA P19793 2/20 0.38
RXRB P28702 2/20 0.38
NR4A2 P43354 1/20 0.38
KCNN4 O15554 1/20 0.38
RXRG P48443 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2582578 0.84 DGAT1 (0.43) MAPTDGAT1CA1CA2KCNN4
SCHEMBL3622009 0.84 DGAT1 (0.43) MAPTDGAT1CA1CA2KCNN4
SCHEMBL1554119 0.84 DGAT1 (0.43) MAPTDGAT1CA1CA2KCNN4
SCHEMBL1525462 0.83 MEN1 (0.43) MEN1CYP1A2KMT2AMAPTDGAT1
SCHEMBL3503826 0.83 KMT2A (0.44) MEN1KMT2AMAPTDGAT1KCNN4
SCHEMBL1525551 0.83 MEN1 (0.43) MEN1CYP1A2KMT2AMAPTDGAT1
SCHEMBL8667721 0.81 NR1H4 (0.44) CYP1A2MAPTNR1H4EPHX2DGAT1
SCHEMBL27521467 0.81 SRD5A2 (0.49) SRD5A2MEN1CYP1A2KMT2AMAPT
SCHEMBL3502202 0.79 KDM4E (0.54) MEN1KMT2AMAPTTP53
SCHEMBL27734342 0.77 MEN1 (0.49) SRD5A2MEN1CYP1A2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190788-A1 Amide derivatives as kinase inhitors DEVGEN N.V. (BE) 2010-07-29 US disclosed
CN-101248046-A Amide derivatives as kinase inhibitors DEVGEN NV (BE) 2008-08-20 CN disclosed
EP-1907362-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen NV (BE) 2008-04-09 EP disclosed
WO-2007006547-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190788-A1 Amide derivatives as kinase inhitors MAP3K1, MAPK1, MAP3K21 SRD5A2 1525/4885MEN1 1063/4885CYP1A2 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.